U.S. Stem Cell, Inc. Logo

U.S. Stem Cell, Inc.

USRM

(1.5)
Stock Price

0,00 USD

0% ROA

0% ROE

-0.11x PER

Market Cap.

64.151,00 USD

0% DER

0% Yield

0% NPM

U.S. Stem Cell, Inc. Stock Analysis

U.S. Stem Cell, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

U.S. Stem Cell, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (-0x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (-61%), which means it has a small amount of debt compared to the ownership it holds

3 ROE

The stock's ROE falls within an average range (8.99%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

5 ROA

The stock's ROA (-1912.93%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

U.S. Stem Cell, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

U.S. Stem Cell, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

U.S. Stem Cell, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

U.S. Stem Cell, Inc. Revenue
Year Revenue Growth
2002 2.000
2003 46.000 95.65%
2004 86.000 46.51%
2005 135.350 36.46%
2006 105.503 -28.29%
2007 312.809 66.27%
2008 57.051 -448.3%
2009 359.800 84.14%
2010 46.383 -675.72%
2011 17.475 -165.42%
2012 61.109 71.4%
2013 96.085 36.4%
2014 2.055.831 95.33%
2015 2.191.177 6.18%
2016 3.083.261 28.93%
2017 5.520.537 44.15%
2018 6.700.888 17.61%
2019 3.072.293 -118.11%
2020 277.087 -1008.78%
2021 200.749 -38.03%
2022 82.049 -144.67%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

U.S. Stem Cell, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2002 7.361.000
2003 3.502.000 -110.19%
2004 3.787.000 7.53%
2005 4.533.820 16.47%
2006 6.878.225 34.08%
2007 11.313.554 39.2%
2008 6.166.777 -83.46%
2009 2.491.189 -147.54%
2010 1.467.078 -69.81%
2011 465.461 -215.19%
2012 401.941 -15.8%
2013 626.983 35.89%
2014 66.420 -843.97%
2015 10.000 -564.2%
2016 919 -988.14%
2017 6.644 86.17%
2018 5.439 -22.15%
2019 263 -1968.06%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

U.S. Stem Cell, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 4.426.632 100%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

U.S. Stem Cell, Inc. EBITDA
Year EBITDA Growth
2002 -9.305.000
2003 -6.009.000 -54.85%
2004 -5.478.000 -9.69%
2005 -7.316.823 25.13%
2006 -13.217.330 44.64%
2007 -11.529.502 -14.64%
2008 -11.621.871 0.79%
2009 -4.431.674 -162.25%
2010 -3.209.070 -38.1%
2011 -2.575.226 -24.61%
2012 -2.520.254 -2.18%
2013 -2.829.560 10.93%
2014 -3.534.079 19.94%
2015 -2.561.866 -37.95%
2016 -1.000.369 -156.09%
2017 -433.553 -130.74%
2018 -642.958 32.57%
2019 -2.955.449 78.24%
2020 -2.423.598 -21.94%
2021 -2.287.268 -5.96%
2022 -1.720.472 -32.94%
2023 0 0%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

U.S. Stem Cell, Inc. Gross Profit
Year Gross Profit Growth
2002 2.000
2003 16.000 87.5%
2004 40.000 60%
2005 47.923 16.53%
2006 32.993 -45.25%
2007 246.979 86.64%
2008 46.089 -435.87%
2009 154.786 70.22%
2010 26.618 -481.51%
2011 16.781 -58.62%
2012 60.039 72.05%
2013 65.254 7.99%
2014 1.210.890 94.61%
2015 1.218.220 0.6%
2016 2.111.252 42.3%
2017 3.635.166 41.92%
2018 4.590.356 20.81%
2019 1.737.056 -164.26%
2020 212.970 -715.63%
2021 148.719 -43.2%
2022 58.282 -155.17%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

U.S. Stem Cell, Inc. Net Profit
Year Net Profit Growth
2002 -9.258.000
2003 -6.038.000 -53.33%
2004 -5.519.000 -9.4%
2005 -7.326.557 24.67%
2006 -13.180.646 44.41%
2007 -18.067.084 27.05%
2008 -14.204.925 -27.19%
2009 -3.844.249 -269.51%
2010 -5.159.456 25.49%
2011 -4.697.037 -9.84%
2012 -4.016.467 -16.94%
2013 -3.143.259 -27.78%
2014 -2.253.511 -39.48%
2015 -1.641.880 -37.25%
2016 -2.070.386 20.7%
2017 -3.481.491 40.53%
2018 -2.160.427 -61.15%
2019 -5.035.130 57.09%
2020 -3.378.862 -49.02%
2021 -4.287.564 21.19%
2022 -3.305.425 -29.71%
2023 0 0%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

U.S. Stem Cell, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 -1.541
2003 -750 -105.74%
2004 -600 -24.83%
2005 -688 12.66%
2006 -1.097 37.37%
2007 -1.368 19.75%
2008 -973 -40.49%
2009 -218 -348.39%
2010 -190 -14.81%
2011 -82 -130.49%
2012 -27 -203.7%
2013 -12 -125%
2014 -5 -200%
2015 -2 -300%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

U.S. Stem Cell, Inc. Free Cashflow
Year Free Cashflow Growth
2005 -6.091.666
2006 -8.032.763 24.16%
2007 -9.831.076 18.29%
2008 -10.997.959 10.61%
2009 -2.026.888 -442.6%
2010 -1.894.245 -7%
2011 -1.693.904 -11.83%
2012 -1.096.209 -54.52%
2013 -1.922.751 42.99%
2014 -1.116.768 -72.17%
2015 -846.725 -31.89%
2016 99.660 949.61%
2017 1.230.231 91.9%
2018 602.467 -104.2%
2019 -1.377.828 143.73%
2020 -478.886 -187.72%
2021 -1.057.939 54.73%
2022 -304.852 -247.03%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

U.S. Stem Cell, Inc. Operating Cashflow
Year Operating Cashflow Growth
2005 -5.765.455
2006 -7.829.497 26.36%
2007 -9.729.081 19.52%
2008 -10.979.029 11.38%
2009 -2.026.200 -441.85%
2010 -1.894.245 -6.97%
2011 -1.693.904 -11.83%
2012 -1.095.276 -54.66%
2013 -1.913.326 42.76%
2014 -1.108.647 -72.58%
2015 -844.690 -31.25%
2016 112.242 852.56%
2017 1.231.393 90.88%
2018 602.467 -104.39%
2019 -1.210.994 149.75%
2020 -478.886 -152.88%
2021 -1.057.939 54.73%
2022 -304.852 -247.03%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

U.S. Stem Cell, Inc. Capital Expenditure
Year Capital Expenditure Growth
2005 326.211
2006 203.266 -60.48%
2007 101.995 -99.29%
2008 18.930 -438.8%
2009 688 -2651.45%
2010 0 0%
2011 0 0%
2012 933 100%
2013 9.425 90.1%
2014 8.121 -16.06%
2015 2.035 -299.07%
2016 12.582 83.83%
2017 1.162 -982.79%
2018 0 0%
2019 166.834 100%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

U.S. Stem Cell, Inc. Equity
Year Equity Growth
2002 788.000
2003 -554.000 242.24%
2004 -1.857.000 70.17%
2005 4.586.432 140.49%
2006 4.310.644 -6.4%
2007 -5.504.964 178.3%
2008 -14.236.047 61.33%
2009 -13.412.371 -6.14%
2010 -12.016.194 -11.62%
2011 -12.010.477 -0.05%
2012 -14.595.567 17.71%
2013 -13.747.076 -6.17%
2014 -10.894.000 -26.19%
2015 -7.721.446 -41.09%
2016 -8.018.644 3.71%
2017 -7.100.317 -12.93%
2018 -6.882.210 -3.17%
2019 -9.479.396 27.4%
2020 -11.579.292 18.13%
2021 -12.766.336 9.3%
2022 -14.745.396 13.42%
2023 0 0%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

U.S. Stem Cell, Inc. Assets
Year Assets Growth
2002 2.540.000
2003 921.000 -175.79%
2004 729.000 -26.34%
2005 5.869.070 87.58%
2006 6.507.980 9.82%
2007 11.324.323 42.53%
2008 1.855.171 -510.42%
2009 1.866.310 0.6%
2010 308.796 -504.38%
2011 268.493 -15.01%
2012 162.310 -65.42%
2013 86.139 -88.43%
2014 204.781 57.94%
2015 229.113 10.62%
2016 427.636 46.42%
2017 1.598.083 73.24%
2018 1.817.089 12.05%
2019 89.843 -1922.52%
2020 88.152 -1.92%
2021 50.999 -72.85%
2022 68.039 25.04%
2023 0 0%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

U.S. Stem Cell, Inc. Liabilities
Year Liabilities Growth
2002 1.752.000
2003 1.475.000 -18.78%
2004 2.586.000 42.96%
2005 1.282.638 -101.62%
2006 2.197.336 41.63%
2007 16.829.287 86.94%
2008 16.091.218 -4.59%
2009 15.278.681 -5.32%
2010 12.324.990 -23.97%
2011 12.278.970 -0.37%
2012 14.757.877 16.8%
2013 13.833.215 -6.68%
2014 11.098.781 -24.64%
2015 7.950.559 -39.6%
2016 8.446.280 5.87%
2017 8.698.400 2.9%
2018 8.699.299 0.01%
2019 9.569.239 9.09%
2020 11.667.444 17.98%
2021 12.817.335 8.97%
2022 14.813.435 13.47%
2023 0 0%

U.S. Stem Cell, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-0.11x
Price To Sales Ratio
3.21x
POCF Ratio
-1.47
PFCF Ratio
-1.49
Price to Book Ratio
0
EV to Sales
3.21
EV Over EBITDA
-0.17
EV to Operating CashFlow
-1.49
EV to FreeCashFlow
-1.49
Earnings Yield
-8.94
FreeCashFlow Yield
-0.67
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0
Graham NetNet
0

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.08
ROE
0.15
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0
EBT Per Ebit
0
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
4.44
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0
Return on Tangible Assets
0
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0
Current Ratio
0
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

U.S. Stem Cell, Inc. Dividends
Year Dividends Growth

U.S. Stem Cell, Inc. Profile

About U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.

CEO
Mr. Michael Tomas
Employee
0
Address
1560 Sawgrass Corporate Parkway
Sunrise, 33323

U.S. Stem Cell, Inc. Executives & BODs

U.S. Stem Cell, Inc. Executives & BODs
# Name Age
1 Mr. Michael Tomas
Chief Executive Officer, President, Chief Financial Officer & Director
70
2 Dr. Sergio Pinski
Medical Director & Member of Scientific Advisory Board
70
3 Ms. Evelyn Flores
Corporate Controller
70
4 Dr. Colleen Robb
Senior Compliance Officer
70
5 Mr. Phil Posa
Senior Vice President of U.S. & International Sales
70

U.S. Stem Cell, Inc. Competitors